- Home
- MGPI vs CVAC Comparison
MGPI vs CVAC Comparison
Compare MGPI & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGPI
- CVAC
- Stock Information
- Founded
- MGPI 1941
- CVAC 2000
- Country
- MGPI United States
- CVAC Germany
- Employees
- MGPI N/A
- CVAC N/A
- Industry
- MGPI Beverages (Production/Distribution)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MGPI Consumer Staples
- CVAC Health Care
- Exchange
- MGPI Nasdaq
- CVAC Nasdaq
- Market Cap
- MGPI 803.7M
- CVAC 818.8M
- IPO Year
- MGPI 1988
- CVAC 2020
- Fundamental
- Price
- MGPI $32.19
- CVAC $3.30
- Analyst Decision
- MGPI Buy
- CVAC Hold
- Analyst Count
- MGPI 6
- CVAC 3
- Target Price
- MGPI $70.67
- CVAC $10.00
- AVG Volume (30 Days)
- MGPI 327.8K
- CVAC 617.5K
- Earning Date
- MGPI 02-26-2025
- CVAC 11-12-2024
- Dividend Yield
- MGPI 1.50%
- CVAC N/A
- EPS Growth
- MGPI 9.02
- CVAC N/A
- EPS
- MGPI 4.82
- CVAC N/A
- Revenue
- MGPI $737,717,000.00
- CVAC $70,565,734.00
- Revenue This Year
- MGPI N/A
- CVAC $742.57
- Revenue Next Year
- MGPI N/A
- CVAC N/A
- P/E Ratio
- MGPI $6.67
- CVAC N/A
- Revenue Growth
- MGPI N/A
- CVAC 75.11
- 52 Week Low
- MGPI $31.81
- CVAC $2.22
- 52 Week High
- MGPI $92.52
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- MGPI 36.86
- CVAC 39.12
- Support Level
- MGPI $32.12
- CVAC $3.53
- Resistance Level
- MGPI $33.92
- CVAC $3.72
- Average True Range (ATR)
- MGPI 1.00
- CVAC 0.18
- MACD
- MGPI 0.16
- CVAC -0.06
- Stochastic Oscillator
- MGPI 22.81
- CVAC 10.96
About MGPI MGP Ingredients Inc.
MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives most of its revenue from the Distillery Solutions segment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.